Optimizing Anti-Seizure Control & Advancing Toward Disease-Targeting Therapies

Rare genetic epilepsies and developmental & epileptic encephalopathies (DEEs) are rapidly emerging as one of the most exciting areas in neuroscience drug development. Driven by significant unmet need, increasing biopharma investment, and the progression of ASOs, gene therapies, RNA-targeted medicines, precision small molecules, and next-generation anti-seizure therapies, the field is moving beyond symptomatic seizure management toward therapies capable of modifying disease biology itself.

The Rare Epilepsy & DEE Drug Development Summit arrives at a pivotal moment for the industry. As developers tackle challenges across translational models, biomarker development, endpoint selection, patient stratification, regulatory alignment, and commercialization, this is the first industry-focused forum dedicated to bringing together leaders across research, translational science, clinical development, medical affairs, and executive leadership.